Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
11C-yohimbine is a radiopharmaceutical used as a Positron Emission Tomography (PET) tracer to image and quantify alpha-2 adrenergic receptors in the brain and peripheral tissues. It is a carbon-11 labeled version of yohimbine, a natural alkaloid that acts as a potent and selective alpha-2 adrenergic receptor antagonist. By binding to these receptors, 11C-yohimbine allows researchers to study the density and distribution of alpha-2 receptors in vivo, which is relevant for investigating various neuropsychiatric and cardiovascular conditions, including depression, anxiety, and hypertension. The tracer is primarily used in clinical research settings rather than routine diagnostic practice.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 11C-yohimbine.